| Laurie Lu Behm, MD | |
|
3401 Mcintosh Cir Ste 100, Joplin, MO 64804-3651 | |
| (417) 782-5500 | |
| (417) 782-8516 |
| Full Name | Laurie Lu Behm |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 35 Years |
| Location | 3401 Mcintosh Cir Ste 100, Joplin, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366493934 | NPI | - | NPPES |
| 206674806 | Medicaid | MO | |
| 100152590F | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 102828 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Freeman Health System - Freeman West | Joplin, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Freeman-oak Hill Health System | 8325942253 | 316 |
News Archive
A large proportion of the world's estimated 9.3 million breast cancer survivors experience menopausal symptoms or clinical manifestations of estrogen deficiency.
Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and hospitalization at two years compared to standard medical care, according to late breaking results from the MITRA-FR study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and simultaneously published in the European Journal of Heart Failure.
Researchers at The University of Kansas Cancer Center are working to fill the knowledge gap between DNA damage and cancer, including developing approaches to manipulate the DNA damage response to treat and prevent disease.
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.
In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.
› Verified 3 days ago
| Entity Name | Freeman-oak Hill Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679517023 PECOS PAC ID: 8325942253 Enrollment ID: O20040218000570 |
News Archive
A large proportion of the world's estimated 9.3 million breast cancer survivors experience menopausal symptoms or clinical manifestations of estrogen deficiency.
Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and hospitalization at two years compared to standard medical care, according to late breaking results from the MITRA-FR study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and simultaneously published in the European Journal of Heart Failure.
Researchers at The University of Kansas Cancer Center are working to fill the knowledge gap between DNA damage and cancer, including developing approaches to manipulate the DNA damage response to treat and prevent disease.
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.
In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laurie Lu Behm, MD Po Box 3810, Joplin, MO 64803-3810 Ph: (417) 347-4662 | Laurie Lu Behm, MD 3401 Mcintosh Cir Ste 100, Joplin, MO 64804-3651 Ph: (417) 782-5500 |
News Archive
A large proportion of the world's estimated 9.3 million breast cancer survivors experience menopausal symptoms or clinical manifestations of estrogen deficiency.
Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and hospitalization at two years compared to standard medical care, according to late breaking results from the MITRA-FR study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and simultaneously published in the European Journal of Heart Failure.
Researchers at The University of Kansas Cancer Center are working to fill the knowledge gap between DNA damage and cancer, including developing approaches to manipulate the DNA damage response to treat and prevent disease.
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.
In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.
› Verified 3 days ago
Mr. Luke Evan Snavely, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 201 S Northpark Ln, Joplin, MO 64801 Phone: 417-622-4768 | |
Mr. Melvin Dean Karges, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 702 E 34th St, Ste 100, Joplin, MO 64804 Phone: 417-782-1700 Fax: 417-782-1747 |